Targeting PD-1/PD-L1 in cancer immunotherapy: An effective strategy for treatment of triple-negative breast cancer (TNBC) patients
Oral GLP-1 Formulations and Future Projections Several companies are developing oral GLP-1 formulations, including Novo Nordisk, Pfizer, and smaller firms, positioning them as potential acquisition targets
If Lilly follows a similar pricing strategy for retatrutide, a range of $1,000 to $1,400 per month would be plausible
Here's a fact that surprised us while researching our latest piece: The cells lining your colon don't run on glucose like the rest of your body
Welli, the AI companion, personalizes your experience and helps set goals
Loss of GLP-2R signaling did not impact the increase in small intestinal length or weight observed with cold stress (Fig